TEVA enters the final week of September with one of the more unusual short-interest trajectories in the pharma space right now — a stock where the borrow market has done a full loop in under a month.
The most striking data point is how rapidly short interest rebuilt after collapsing to near-zero. Through August and into early September, estimated shares short were trivially small — under 250,000 shares on most days. Then, starting around September 11, the position grew aggressively: 300,000 shares became 1.5 million by September 14, then 3.8 million by September 16, before pulling back to roughly 3.1 million on September 22. That represents a month-over-month increase of more than 1,500% in raw share terms. The 1-week change of +105% captures only the most recent leg of that rebuilding. To be clear, in absolute terms the short position remains modest relative to Teva's roughly 1.2 billion shares outstanding — this is a story about the velocity and shape of the move, not about a crowded short book.
The borrow market tells a complementary story, though it points in the opposite direction from the SI surge. Availability is extremely loose — sitting at 1,217% of current short interest, well above the 52-week tightest reading of 106%. Roughly 268 million shares remain available to borrow across the lending pool, and the cost to do so has collapsed from around 3.2% on September 15 to just 0.76% by September 22, a decline of 76% in a single week and 60% over the past month. That sharp drop in borrow cost, occurring simultaneously with rising short positions, is somewhat counterintuitive — it suggests the new short demand was easily absorbed by a deep and willing lending pool. There is no squeeze pressure here. Options positioning leans modestly defensive, with the put/call ratio at 0.57, close to its 52-week high of 0.58 hit the prior session, though without a full 20-day mean and z-score the read is limited. The PCR has drifted up from a low of 0.44 in mid-September, consistent with incrementally more hedging as shorts rebuilt.
The Street backdrop for Teva is constructive. Analyst data in this snapshot predates the six-month threshold and cannot be cited as current guidance. What the factor scores do show is that Teva ranks in the 85th percentile on days-to-cover and the 73rd percentile on short score — both elevated relative to the broader market — while the ORTEX short score itself has eased to 30.7 from a recent peak near 33.3 on September 16, tracking the modest pullback in SI shares. The stock has gained 6.8% over the past month to close at $39.52 on September 22, absorbing a 1.3% slip on the day. Dividend history is deeply stale — the last payment was in late 2017 — so income positioning plays no role in the current setup.
The earnings calendar is the cleanest catalyst on the horizon. Teva's last print, on July 29, produced a 30% single-day gain. That kind of reaction history tends to keep option premiums elevated heading into the next announcement, now pencilled in for November 4. The institutional register shows BlackRock holding roughly 6% of shares and Vanguard near 3.7%, both with only marginal recent changes — the kind of passive anchor that moderates float dynamics but rarely drives short-term price action.
The next variable worth tracking is whether the short interest rebuild sustains or fades into October. Given ultra-loose availability and falling borrow costs, there is no structural impediment to either more accumulation or quick unwinding — which makes the November 4 earnings date a sharper-than-usual pivot point for positioning on both sides.
See the live data behind this article on ORTEX.
Open TEVA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
